• about
    • About Jounce
    • Management
    • Board of Directors
    • Company Founders
  • our approach
    • Focus on Patients
    • Why We Do What We Do
    • Mobilizing the Immune System to Attack Cancer
    • What Makes Us Different
    • A History of Promising Science
  • our pipeline
    • Pipeline
    • Publications
    • ICOS Agonist Program – Vopratelimab
    • JTX-4014
    • JTX-8064
    • GS-1811
    • Innovative and Sustainable Discovery Pipeline
  • investors & media
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Publications
    • Financial Information
    • Annual Meeting
    • Corporate Governance
    • Email Alerts
    • Investor FAQ
  • join #onejounce
    • Life at Jounce
    • Diversity & Inclusion
    • Core Values
    • Current Openings
follow
contact
main menu

Diversity & Inclusion

Pages

  • Home
  • About
  • Our Approach
  • Our Pipeline
  • Investors and Media
  • Join #OneJounce
  • Career Opportunities

Resources

  • Press Releases
  • Contact Contact

Leadership

  • Management Team
  • Board of Directors
  • Company Founders

Focus

  • Pipeline Overview
  • T Cell Approach
  • Beyond T Cell

© Jounce Therapeutics, Inc. All rights reserved. | Privacy Policy | Terms of Use

Contact Us

Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
Mark Yore
(857) 200-1255
myore@jouncetx.com